Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Cancer Targets 2018

About Cancer Targets 2018

Cancer target 2018  is organized around the theme: “A Lifesaving mission to end cancer forever”.

ME Conferences welcomes you to the International Conference on Biomarkers and Cancer Targets 2018 to be held on December 5-6,2018 in Dubai UAE. Cancer Target 2018  is a well organised scientific event consisting workshops, symposiums, exhibitions of oncological instruments, new diagnostic therapies and special sessions for young researchers and students with modern and advance research from top universities, research centres, hospitals.

The unique international on biomarker and cancer target conference 2018 directs towards addressing main issues as well as future strategies s of cancer. This is going to be the largest and most promising international conference where the researcher as well as decision makers will come to discuss and debate on various aspects of the challenges, risks and investment opportunities throughout the complete information of cancers. The program includes the complete information of cancers including cancer target therapy, Cancer nursing and care, Economic impact on cancer, Biomarker and  advance use of biomarkers, the entire medical team involved in patient care ,researcher, Professional, early career individuals and patient advocates who wish to learn principles of tumour immunology and immunotherapy.

ME Conferences organizes 3000+ Global events in conference series every year across the globe with support from 1000+ more scientific societies and Publishes 700 open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board members.


Target Audience:

  • Oncologists
  • Pathologists
  • Hematologists
  • Immunologists
  • Clinical Researchers
  • Nursing
  • Cancer  Researchers
  • Scientists
  • Young Researchers
  • Students
  • Biomarker Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies
  • Pharmaceutical Companies
  • Diagnostics Companies

Sessions/Tracks

Track 1: Cancer

Cancer is a gathering of sicknesses including irregular cell development with the possibility to attack or spread to different parts of the body. These stand out from benevolent tumours, which don't spread to different parts of the body. Possible signs and side effects incorporate a bump, strange dying, delayed hack, unexplained weight reduction, and an adjustment in gut movements. Tobacco use is the cause of about 22% of cancer deaths. Another 10% are due to obesity, poor diet, lack of physical activity, and excessive drinking of alcohol. Other factors include certain infections, exposure to ionizing radiation and environmental pollutants. In the developing world, 15% of cancers are due to infections such as Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus infection, Epstein–Barr virus and human immunodeficiency virus.

  • Colorectal cancer
  • Non-Hodgkin lymphoma
  • Prostate cancer
  • Lung cancer
  • stomach cancer

 

Track 2: Cancer Biomarkers

Cancer biomarkers can be DNA, mRNA, proteins, metabolites, or processes such as apoptosis, angiogenesis or proliferation. The markers are produced either by the tumor itself or by other tissues, in response to the presence of cancer or other associated conditions, such as inflammation. Such biomarkers can be found in a variety of fluids, tissues and cell lines. "A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

  • Diagnostic (screening) biomarker
  • Prognostic biomarker
  • Stratification (predictive) biomarker

 

Track 3: Cancer Biomarkers in Clinical Use    

Biomarkers play a key role in the diagnosis and management of patients with cancer, and are important for fulfilling the promise of precision medicine in oncology. However, although numerous biomarkers have been shown to have clinical validity, many have not undergone rigorous testing to demonstrate clinical utility so that they can be appropriately incorporated into clinical care. This review article highlights the characteristics of a good biomarker and the steps required to demonstrate clinical utility, and gives examples of both successful established biomarkers and promising new tissue-based and circulating biomarkers on the horizon.

  • Circulating tumour cell
  • circulating tumour DNA
  • clinical utility

 

Track 4: Types of Biomarker and Biomarkers

A Biomarker is the organic particle found in blood, other body liquids, or tissues that is an indication of a typical or anomalous process, or of a condition or disease. A biomarker might be utilized to perceive how well the body reacts to a treatment for a malady or condition. Likewise called molecular marker  and mark  particle. Cancer biomarkers are arranged by their diverse capacities: Biomarkers that Trigger Cells to Grow and Multiply Abnormally, Biomarkers That Support a Treatment's Cellular or Molecular Action, Biomarkers That Disrupt a Treatment's Cellular or Molecular Action, Detecting and Measuring Biomarkers to Develop a Personalized Anticancer Treatment Plan.

  •  Genomic biomarker
  •  Transcriptomic biomarker
  •   Metabolomics  biomarker
  •   Drug activity markers
  •   Imaging biomarker     
  • Proteomic biomarker

 

Track 5: Surgical oncology

Surgical oncology is the branch of surgery applied to oncology; it focuses on the surgical management of tumours, especially cancerous tumours. Surgery is used to diagnose, stage and treat cancer, and certain cancer-related symptoms. Surgeons have performed thousands of procedures and will discuss appropriate surgical options that meet your individual needs. Childhood cancers are different from adult cancers. The Advanced Surgical Recovery Program (ASURE) is designed to help patients recover from surgery more quickly and with fewer complications. Lymphadenectomy. ASURE is intended to improve surgical outcomes and enhance the patient experience before, during and after surgery, while also reducing patients’ overall hospital stay.

  • Pancreaticoduodenectomy
  • Thyroidectomy
  • Appendix surgery

 

Track 6: Pediatric Oncology

Childhood growth (otherwise called pediatric malignancy) is disease in a kid. Pediatric oncology is the branch of medication worried about the determination and treatment of disease in kids. A pediatric oncologist spends significant time in research and treatment for growths that create in babies, little children, youngsters, youths and adolescents. This is one reason why there is a requirement for pediatric oncologists who are prepared in treating the two youngsters and growth. Numerous pediatric oncologists additionally represent considerable authority in hematology, which is the investigation and treatment of sicknesses identified with the blood. These specialists are in some cases alluded to as pediatric oncologists/hematologists

  • Neuroblastoma
  • Wilms tumour
  • Pediatric Neuro  oncologist
  • Hepatoblastoma and hepatocellular carcinoma

 

Track 7: Haematologist-oncology

A haematologist-oncologist is a physician who specializes in the diagnosis, treatment and/or prevention of blood diseases and cancers such as iron-deficiency anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. This physician is trained in haematology — the study of blood — and oncology — the study of cancer. Hematologist-oncologists do not usually treat operable cancers such as prostate cancer, but specialize in treating blood cancers, such as Hodgkins and non-Hodgkins lymphomas, leukemias and multiple myelomas.

  • Haemophilia
  • Bone marrow disease
  • Anticoagulation therapy
  • Blood transfusion

 

Track 8: Gynecologist oncology

A gynaecologist oncologist is a physician who specializes in diagnosing and treating cancers that are located on a woman’s reproductive organs The gynecologic oncologist serves as the captain of a woman’s gynecologic cancer care team. A gynaecologic oncologist is a specialist in obstetrics and gynaecology who by virtue of education and training is prepared to provide consultation on and comprehensive management of patients with gynaecologic cancer and whose present activity includes the practice of gynaecologic oncology in an institutional setting wherein all the effective forms of cancer therapy are available.

  • Cervical Cancer
  • Vaginal Cancer
  • Diagnostic tests
  • Ovarian cortex cryopreservation
  • Vulvar cancers

 

Track 9: Orthopaedic Oncology

An orthopaedic (orthopaedic) oncologist is a physician and surgeon who specialize in the diagnoses and treatment of primary benign and malignant tumors of the bones. The Division of Orthopaedic Oncology offers expert care to children and adults diagnosed with tumours and tumour-like conditions of the bone and soft tissue, including bone metastases, sarcomas, benign and cancerous tumors of the bone or soft tissue and pathologic fractures. Treatment of various forms of primary benign and malignant neoplasms of the bones and bony structures of the human body (any cancer which has originated from the bone, as opposed to cancers which originated from other organs and have secondarily spread, or metastasized, to the bones, which is much more common; these specialists deal mostly with primary bone tumors).

  • Musculoskeletal Radiologists
  • Malignant Bone Tumours
  • Ewing's sarcoma
  • Chondrosarcoma

 

Track 10: Breast Cancer

Breast cancer begins in the cells of the breast. A harmful tumour is a gathering of growth cells that can develop into and annihilate close-by tissue. It can likewise metastasize to different parts of the body. Cells in the breast some of the time change and never again develop or act ordinarily. These progressions may prompt non-malignant bosom conditions, for example, atypical hyperplasia and sores. They can likewise prompt non-carcinogenic tumours, for example, intraductal  papillomas.  Breast cancer screening

  •   Breast reconstruction
  •   Lobular carcinoma
  •   Abortion–breast cancer hypothesis

 

Track 11: Neuro-oncology

Neuro-oncology is the investigation of cerebrum and spinal string neoplasms, a significant number of which are (at any rate in the end) extremely perilous and hazardous (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and mind stem tumours are among the numerous cases of these).

  • Neuro-oncologists
  • Head and Neck Surgery
  • Neuropathology Department
  • spectroscopic imaging
  • Helical Multi Detector CT Scanners

 

Track 12: Pathophysiology of Cancer

Pathophysiology of cancer incorporates reason for the sickness, conclusion, how the infection creates, instrument and characteristic course of the illness. They additionally manage biochemical highlights, movement, and guess or result of the ailment. Pathology of  tumours and other complex issue have experienced an ocean change after improvement of innovations like immunohistochemistry, stream cytometry, and sub-atomic biologic ways to deal with malignancy analysis. 

  •  Genetic changes
  •  Genomic amplification
  •  Translocation
  •  Solid tumour parts

 

Track 13: Cancer Pharmacology

Cancer pharmacology incorporate investigations of the fundamental mechanism of signal transduction related with cell multiplication and apoptosis, the mechanism  of activity of anti-neoplastic specialists, the outline and revelation of new medications, essential components of DNA repair and DNA harm resilience and the advancement of novel techniques for quality treatment. 

  • Human cancer cell lines
  • Genetic manipulation of cancer
  • Malignant transformation
  • Cancer cell proliferation

 

Track 14: Cancer Therapeutics

Atomic Cancer Therapeutics will concentrate on fundamental research that has suggestions for growth therapeutics in the accompanying zones: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The diary gives a production discussion to these rising orders that is centered particularly around disease look into. Papers are stringently looked into and just those that report aftereffects of novel, opportune, and noteworthy research and meet exclusive expectations of logical legitimacy will be acknowledged for production.

  •  Molecular cancer Therapeutics
  •  Neurotherapeutics
  •  Pharmacology and clinical Toxicology
  •  Therapeutics
  •  Biomolecules and Therapeutics

 

Track 15: Homeopathy Cancer Treatment

Homeopathic drugs have proven biological action in cancer; in vitro and in vivo; in animals and humans; in the lower, as well as in the higher potencies. Cancer patients are faced with a life-and-death decision when choosing their treatment. Since most conventional treatments continue to be associated with severe adverse and some- times fatal effects, while homeopathy has been found to be free from such effects, it would seem plausible and worthwhile, even urgent, to step up the research on, and even the provision of, homeopathic treatment of cancer and other diseases.

  • Psorinum Therapy of Cancer
  • Homeopathic drugs
  • Homeopathic Cancer Research
  • Beneficial clinical effects of Homeopathic drugs
  • Anti-cancer Effects of Homeopathic Drugs
  • Research Methodologies and Mechanism of Action

 

Track 16: Cancer Epigenetics

Cancer epigenetics is the investigation of epigenetic alterations to the DNA of malignancy cells that don't include an adjustment in the nucleotide arrangement. Epigenetic changes might be similarly as vital, or much more critical, than hereditary changes in a cell's change to malignancy. A variety of compounds are considered as epigenetic carcinogens such as arsenite, diethylstilbestrol, hexachlorobenzene and nickel compounds. They result in an increased incidence of tumors, but they do not show mutagen activity.

  • DNA binding proteins
  • Histone modification
  • Genetic mutations
  • Tumour suppressor gene

 

Track 17: Cancer: Lifestyle and Nutrition

Cancer is to a great extent an inherited infection, as though destiny and the family quality pool alone direct your odds of becoming ill. A sound eating routine is fundamental to tumour anticipation, particularly a regimen concentrated on settling on nutritious decisions, favouring natural nourishment, eating with some restraint and preparing foods properly . It's about adjust, control and assortment. By eating the correct nourishment, expending a wide range of supplements and not devouring more than your body requires, you can help decrease your danger of malignancy and different illnesses.

  • Control your weight
  • Be more active
  • Eat healthy foods
  • Healthy Lifestyle

 

Track 18: Cancer Prognosis and Predictive Factor

prognostic factor is an element of the malignancy (like the extent of the tumour) or a normal for the individual (like their age) that may influence the result. A predictive factor can help foresee if a malignancy will react to a specific treatment. A few medications just work if atoms, (for example, proteins) are on growth cells or inside them. These are some essential prognostic elements identified with the tumour: The sort of disease, The subtype of malignancy in light of the sort of cells or tissue (histology), The extent of the tumour, How far and where the malignancy has spread, How quick the malignancy cells are developing. Important predictive elements incorporate a few sorts of tumour markers, biomarkers and changes to chromosomes (hereditary transformations).

  •  Human papillomavirus infection
  •  Adrenal Carcinoma Prognosis
  •  Lymphoma Prognosis
  •  Basal Cell Carcinoma Prognosis
  •  Mucoepidermoid Carcinoma Prognosis

 

Track 19: Cancer Proteomics

Proteomics advancements are utilized for early discovery and finding of diseases for the improvement of novel restorative operators. Distinguishing proof of biomarker and furthermore the investigation of protein articulation of the disease are examined through proteomics stages. These investigations have prompted the advancement of finding new medications and focused on therapeutics towards the tumour cells. Identification, anticipation, finding and treatment of breast malignancy is presently conceivable with the headways in the field of proteomics alongside the utilization of mass spectrometry. The disclosure of the protein designs has empowered scientists to recognize the disease and disease free-state related with breast disease has been revealed with the improvement of proteomics advancements. This revelation prompts customized treatment for the patients. Proteins communicated or found in the serum, plasma and the tumour cells utilizing the novel procedures give a superior perspective of the heterogeneity of the diseases.

  •  Genes and protein altered in cancer
  •  Protein expression of cancer genes
  •  Tumour biology
  •   Leukaemia and lymphoma

 

Track 20: Molecular Epidemiology of Cancer

Cancer Molecular epidemiology is a branch of oncology and epidemiology that focuses on the contribution of potential environmental and genetic risk factors, identified at the molecular level, to the etiology, distribution and prevention of cancer within families and across populations. The goal of molecular epidemiology is to supplement and integrate existing methods. Molecular epidemiology of cancer studies molecular markers of distribution of malignant tumours in the population and their effects on individual risk of developing a disease. Molecular markers can be detected in tissues and biological liquids and characterize individual exposure to carcinogens, biological effect of the exposure, genetic susceptibility to the development of disease, and final result of carcinogenesis. Identification of specific somatic molecular and genetic changes, so-called fingerprints, is very important for the molecular characteristics of a tumour and confirmation of etiology.

  •  Disease surveillance
  •  Case series
  •  Case-control studies
  •  Prostate cancer screening
  • Prostate-specific antigen

 

Track 21: Cancer Nursing and Care

There are various types of nurse care associated with cancer treatments. Authority  medical attendants, ward medical care takers, Community medical care takers, Specialist palliative care medical attendants, Marie Curie Cancer Care Nurses. Authority attendants work primarily in doctor's facilities, however some give mind in the patient's home. They may have some expertise in a particular malignancy for instance bosom, lung, head and neck disease, or a specific treatment, for instance chemotherapy. Community attendants give an extensive variety of nursing care including helping patients when they leave clinic, taking out fastens, wiping wounds and giving out some prescription at home. Authority palliative care medical care takers have skill in overseeing torment and different manifestations, and can offer help for individuals with growth and their families. Marie Curie medical caretakers give hands on mind at home during that time or night, offering the carer a reprieve. They will have exceptional learning of palliative care.

  • Anticipatory grieving   
  • Altered Nutrition: Less than Body Requirements·   
  • Risk for Fluid Volume Deficit
  •  Risk for Infection

 

Track 22: Cancer Diagnosis

There are several methods of diagnosing cancer. With advances in technologies that understand cancers better, there is a rise of number of diagnostic tools that can help detect cancers. Once suspected, diagnosis is usually made by pathologists and oncopathologists and imaging radiologists. Diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. Diagnostics plays an important role throughout your cancer treatment it includes Before treatment, During your treatment, After you complete treatment.

  • Biopsy
  • Sentinel node biopsy
  • Endoscopy
  • Blood tests
  • Bone marrow aspiration

 

Track 23: Cancer Biopsy

The expulsion of cells or tissues for examination by a pathologist. The pathologist may ponder the tissue under a magnifying lens or perform different tests on the cells or tissue. There are a wide range of sorts of biopsy techniques. The most widely recognized sorts include: (1) incisional biopsy, in  which just an example of tissue is evacuated; (2) excisional biopsy, in which a whole irregularity or suspicious zone is expelled; and (3) needle biopsy, in which a specimen of tissue or liquid is expelled with a needle. At the point when a wide needle is utilized, the strategy is known as a center   biopsy. At the point when a thin needle is utilized, the methodology is known as a fine-needle goal biopsy.

  •   Bone marrow aspiration and biopsy
  •   Endoscopic biopsy
  •   Needle biopsy
  •   Tumour Marker Tests

 

Track 24: Magnetic Resonance Imaging (MRI)

Magnetic resonance imaging (MRI) is a scanning procedure that uses strong magnets and radiofrequency pulses to generate signals from the body. These signals are detected by a radio antenna and processed by a computer to create images (or pictures) of the inside of your body. The MRI scanner is generally shaped like a large, covered box with a tunnel passing through it. A table, on which you lie, slides into the tunnel. Both ends of the scanner are open and will not close. The tunnel has lights in it and sometimes a mirror..

  • Real-time MRI
  • Interventional MRI
  • Medical imaging
  • NMR applications
  • Diagnostic medicine

 

Track 25: Factors Associated with Cancer Prevalence

The association between cancer prevalence and race, income, insurance, and education was estimated using the Medical Expenditure Panel Survey   data from 1996-2007. The goal of this analysis was to provide some insight into how variations in race and socioeconomic factors influence the prevalence of cancer. This analysis was conducted for any cancer and for the four most common cancer sites i.e lung, colorectal, breast and prostate. Initially, the model was estimated using MEPS data from 2002-2007 to include body mass index, exercise and smoking behaviour as predictors in the model. This data is not available in the MEPS for the prior years. We compared the results of our model with and without these variables and concluded that they did not confound the associations between cancer prevalence and race, income, insurance, and education. Therefore, we dropped these variables from the analysis and were able to expand our data to include the years 1996-2001. This increased the number of persons with cancer in our analysis and was important for our analysis of the four most common cancer sites.

  •   Cancer-Causing Substances.
  •   Chronic Inflammation
  •   Immunosuppression
  •    Infectious agents

 

Track 26: Cancer Pharma Industry

Tumour is one of the best wellbeing challenges, and a main source of death in each edge of the world. The worldwide market for Cancer drugs is anticipated to develop twice as quick as that of different pharmaceuticals throughout the following couple of years. Top organizations incorporate Janssen biotech, Takeda oncology, Boehringer   ingelheim, Roche, Novartis, Celgene, Johnson and Johnson, and Amgen. The growth business is the most ordinarily profitable business in the USA. It has been seen that, there are 1,665,540 new malignancy cases analysed and 585,720 growth passing in the US in the year 2014. $6 billion of citizen stores are spun through different government organizations for malignancy explore for the most part as the National Cancer Institute . The NCI states that the restorative expenses of disease mind are $125 billion, with the ascent of 39 percent to $173 billion by the up and coming year that is 2020. The most well-known maxim of the growth business is it utilizes an excessive number of individuals and delivers excessively pay to enable a cure to be found.

  •  Cancer drugs
  •  Novartis
  •  Johnson & Johnson
  •  Cancer research
  •   National Cancer Institute

 

Track 27: Economic Impact on Cancer

The financial costs of cancer are high for both the person with cancer and for society as a whole. The Agency for Healthcare research and Quality (AHRQ) estimates that the direct medical costs (total of all health care costs) for cancer in the US in 2014 were $87.8 billion.58% of this cost is for hospital outpatient or doctor office visits, 27% of this cost is for inpatient hospital stays. These estimates are based on a set of large-scale surveys of individuals and their medical providers called the Medical Expenditure Panel Survey (MEPS).  One of the major costs of cancer is cancer treatment. But lack of health insurance and other barriers to health care prevent many Americans from getting optimal health care. According to the US Census Bureau, about 29 million people (9%) in the US were uninsured in 2015.The percentage of uninsured ranged from 3% in Massachusetts to 17% in Texas.

  •  Medical Expenditure Panel Survey
  • Large-scale surveys of individuals
  •  Agency for Healthcare research and Quality

 

   

Related Conferences: Cancer Targets Conferences | Biomakers Congress | Cancer Research Events | Oncology and Radiology Meetings | Cancer Stem Cell Conference

 

Related Societies:

American Society of Clinical OncologyEuropean Society For Medical OncologyInternational Agency for Research on CancerInternational Society of Geriatric OncologyInternational Society of Paediatric OncologyEuropean Society of Breast Cancer SpecialistsEuropean Society of Surgical Oncology

Other Related Societies:

USA: American Cancer SocietyAmerican Childhood Cancer OrganisationAmerican Society for Blood & Marrow TransplantationAmerican Society for Colposcopy and Cervical PathologyAmerican Society of Clinical OncologyAmerican Society of HaematologyAmerican Society of Paediatric Oncology ,American Association for Cancer ResearchAmerican Brest Cancer FoundationHematology/Oncology Pharmacy AssociationInternational Agency for Research on Cancer (IARC)

Europe: European Cancer OrganisationEuropean Cervical Cancer Association , European Head and Neck cancer AwarenessEuropean Hematology AssociationEuropean society of molecular imagingUK Oncology Nursing SocietyUnited Kingdom Association of Cancer RegistriesChildhood Cancer Research Group Cancer Focus BASOEuropean Society of Oncologic ImagingEuropean Association for Cancer ResearchEuropean Society for Medical OncologyEuropean Society for Medical OncologyUK Oncology Nursing Children’s Cancer and Leukaemia Group Society,  EFB European Federation of Biotechnology,  European Diagnostic Manufacturers Association,  European Society of Pathology  ICGEBInternational Center for Genetic Engineering and Biotechnology

Asia Pacific: Chinese Society for Cell Biology (CSCB), Chinese Society of Biochemistry and Molecular BiologyThe Hong Kong Society of Biochemistry and Molecular BiologyThe Chinese Biological Investigator SocietyAustralian Society for Biochemistry and Molecular Biology,    Chinese Society for Biochemistry and Molecular Biology ,    Korean Society for Biochemistry and Molecular Biology (KSBMB)The Federation of Asian and Oceanian Biochemists (FAOB),  Japan Society for Molecular ScienceThe Genetics Society of Japan (GSJ)Fungal Molecular Biology Society of JapanAssociation for Molecular Pathology (AMP)Molecular Pathology Association of India (MPAI).

Middle East : Moazzara – Emirates Association for Cancer SupportAngels of Mercy Cancer SocietyFriends of Cancer Patients Society,  Association for Molecular PathologyThailand division of International Academy of PathologyTaiwan Society of PathologyIndonesian Association of Clinical Pathology and Laboratory MedicineRomanian Society of Biochemistry and Molecular BiologyRomanian Society of Human GenomicsThe Malaysian Biochemical SocietyMalaysian Society for Molecular Biology and Biotechnology

 


Market Analysis

Theme: “A Lifesaving mission to end cancer forever”

Scope and Importance

Cancer is the uncontrolled growth of abnormal cells in the body. Cancerous cells are also called malignant cells. Cancer grows out of cells in the body. Normal cells multiply when the body needs them, and die when they are damaged or the body doesn't need them. Cancer appears to occur when the genetic material of a cell becomes changed. This results in cells growing out of control. Cells divide too quickly and do not die in a normal way. Some cancers are more common in certain parts of the world. For example, in Japan, there are many cases of stomach cancer. But in the United States, this type of cancer is less common. Differences in diet or environmental factors may play a role.  Cancer affects many people. It is not limited by gender, age, or ethnicity and has no physical barriers within the body. In America alone, as of 2007, 27% of Americans had or were being treated for some form of cancer.

Why it’s in Dubai, UAE:

Cancer target 2018   is going to held in Dubai. Dubai is the largest and most populous city in the United Arab Emirates (UAE). It is located on the southeast coast of the Persian Gulf and is the capital of the Emirate of Dubai, one of the seven emirates that make up the country. Dubai was ranked 44th among the world's best financial cities and the world's 27th richest city in 2012. It is also an international financial center and has been ranked 37th within the top 50 global financial cities and 1st within the Middle East. As indicated by an examination give an account without bounds intensity of urban communities, in 2025, Dubai will have climbed to 23rd place in general in the Index.. Public hospitals in Dubai were first built in the late 1950s and continued to grow with public health initiatives. There are now 28 hospitals in Dubai, 6 public and 22 private, with 3 more major hospitals scheduled to be built by 2025. Tumour examine is basically going ahead in Asian nations close to Dubai, so it is a reasonable goal for Oncology and malignancy gatherings.

Why to attend???

With members from around the world focused on learning about biomarkers and cancer biomarkers, and its advances; this is your best opportunity to reach the largest assemblage of participants from the biomarker community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in  and cancer biomarkers are hallmarks of this conference.

Cancer is a disease in which abnormal cells divide uncontrollably and destroy body tissue.  There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery.

Cancer is a complex medical issue that requires a multidisciplinary approach. This approach is sweeping and ranges from well-being advancement to counteractive action and screening, diagnosis, treatment, restoration and palliative care.

5 Most common cancers in Dubai

  • Cancer is the third leading cause of death in the Emirate of Abu Dhabi. It is the third among nationals and the third among expatriates. It accounts for 16% of total deaths.

  • There were around 427 deaths caused by cancer in 2015, 35% were nationals and 65% were expatriates.

  • 44% of death were females and 56% were males

  • The top five Leading causes of death among cancers in men (in order of frequency) are Lung, Colorectal, Liver, Leukemia and Pancreas.

  • The top five Leading causes of death among cancers in Women (in order of frequency) are breast, Colorectal, Leukemia, Ovary, and Lung.

Major Associations

In Dubai

Ernakulam Pravassi Welfare Association

Ananthapuram Non Residents Association

Venjaramoodu Non Resident Malayalee

Dubai Charity Association

Dubai Chamber Of Commerce & Industry

In UAE

Emirates Medical Association

Emirates Society of Hematology

Dubai Health Authority

Middle East cancer consortium

Worldwide

Union for International Cancer Control

International Fanconi Anemia Registry (IFAR)

Armenian Association of Hematology & Oncology

Cancer Association of South Africa

Canadian Cancer Sociey

Society for Paediatric Oncology & Hematology

Chinese Society of Clinical Oncology

Cancer Research UK

Indian Association of blood cancer & Allied Diseases

The Leukaemia and Lymphoma Society of Canada

Leukaemia Cancer Society

Leukaemia & Blood Cancer New Zealand

Korean Cancer Association

Fanconi Anaemia Australia

Leukaemia Foundation of Australia

Indian Cancer Society

Brazilian Lymphoma & Leukaemia Association

Chronic Myelogenous Leukaemia Society of Canada

Children’s Cancer and Leukaemia Group

German Cancer Society

Lymphoma Foundation Canada

Cancer Society of Finland

France Lymphoma Hope

Leukaemia &Blood Cancer, New Zealand

Medical Oncology Group of Australia

Australian & New Zealand Children’s Hematology/Oncology Group

Childhood Cancer Research Group, UK

National Cancer Institute of Argentina

Cancer Society Nepal

Top Universities

 In Dubai

Murdoch University, Dubai

Heriot Watt University Dubai Campus

Modul University Dubai

Middlesex University Dubai

Hamdan Bin Mohammed  Smart University

Curtin University Dubai

University of South Wales Dubai

Emirates Aviation University

 In UAE

Al Ghurair University (AGU)

University of Dubai (UD)

Zayed University

American University in Dubai (AUD)

British University in Dubai (BUiD)

American University in the Emirates (AUE)

 Worldwide

University of Chicago, Chicago

University of Toronto, Canada

Washington University in St. Louis

Thomas Jefferson University

National University of Singapore (NUS), Singapore

Indianapolis University “La Sapienza” of Rome, Rome, Italy

University of Wisconsin, Madison-

University of Tokoyo, Japan

Guangxi Medical University, Nanning, China

University of Lyon, France

University Of Leeds

University Of Queensland,Australia

University of Arizona Cancer Center

University of Utah

Georgetown University Medical Center

 University of Southampton

University of Pittsburgh

 McMaster University

University Of Florida

Vanderbilt University School of Medicine

Wayne State University School of Medicine

University of Alberta

University Of British Columbia

University Of Leicester

 University Of Chester

University of Kentucky

University of north Durham

 University Of Surrey

 University Of Edinburgh

 University of Glasgow

 University Of Bordeaux, France

Oregon Health and Science University

 Knight Cancer Institute

Loyola University Chicago

University of Louisville

 University of Toledo

Rutgers University

University Of Calgary

University Of Witaterstrand

University Of Western Sydney, Australia

University of Melbourne

University Of South Australia

University Of New South Wales

Monash University, Australia

University of Milan, Italy

Kyoto University, Japan

The University of Auckland, NZ

University Of Zurich

National Taiwan University

The University of Manchester, UK

Ichan School of medicine, Mount Sinai

Pondicherry University, India

University of phoenix

Griffith University

University Of Exeter

Crimea State Medical University,Ukriane

 Heidelberg University

 Hackensack University Medical Center

 Kyoto University, Taiwan

 Osaka University, Japan                                   

 Kursk State Medical University, Russia

The market of disease is imparted to indicate steady advancement rate in the midst of the gauge time allotment from 2015 – 2020. This advancement is driven by primary contemplations, for instance, rising transcendence of various contaminations and wide R&D rehearses are advancing over the globe to bring new and more fruitful solutions and plans in the market.

Movement in advancement altered pharmaceutical, monetarily adroit treatment techniques are couple of various parts expected to keep up the improvement of overall malignancy treatment grandstand. Be that as it may, exceptional nature of blood illnesses and growing stringency in the regulatory essentials are a bit of the genuine limitations compelling the advancement of overall tumor treatment grandstand.

The overall market for Oncology prescriptions was surveyed to be $25.8 billion of every 2015. By 2017, the market is depended upon to reach $42.5 billion, creating at a CAGR of 12% in the region of 2015 and 2017. The total overall market for oncology issue pharmaceuticals and diagnostics in 2015 was evaluated at practically $82.3 billion. By 2017, the market is depended upon to reach $99.3 billion, creating at a compound yearly advancement rate (CAGR) of 7.2% in the region of 2015 and 2017. The overall tumor issue publicize segment is assessed at $53.3 billion out of 2015 and is depended upon to reach about $76.7 billion by 2017. The genuine reason behind the low advancement rate is the typical diminishing in the yearly cost of treating disease issue and the patent failures of Lovenox, Plavix, Procrit/Epogen, Aranesp, and Neulasta. In 2010, each one of these drugs together accomplished pay of $32 billion into the overall blood issue publicize.

Oncology Drugs Market Overview:

Worldwide Oncology/Cancer Drugs Market is relied upon to collect $111.9 billion by 2020, enlisting a CAGR of 7.1% amid the estimate time frame 2014 to 2020. Late advance in natural treatments has broadened the size of remedial focuses for treatment of malignancy with the distinguishing proof of tumour cell particular qualities. Immunotherapies/biologics are rising as potential treatments to locate the perpetual cure for different growth sorts. Among different biologics, drugs in light of monoclonal antibodies (mAbs) have increased critical consideration as of late because of their high adequacy.

Worldwide growth drugs advertise represented $78,238.9 million out of 2015. The tumour drugs advertise is driven by the developing predominance of different sorts of malignancy, expanding interest of organic and focused on sedate treatments, ceaseless patent expiry of key disease drugs and the rising effect of biosimilars. Be that as it may, the high cost of medication advancement, the danger of disappointment and the unfavourable impacts of tumour tranquilize treatment, especially chemotherapy, prevents the market development. Created countries have executed strict controls for the plan and improvement of disease drugs. USFDA and European Union have embraced noteworthy activities to fuel the development of the malignancy drugs advertise by giving pre-showcase endorsement to potential medications under clinical improvement. Asia-Pacific and LAMEA are promising districts for leading clinical trials due an extensive populace base and the minimal effort of clinical trials when contrasted with North America and Europe. In any case, progression of disease sedate research attributable to organic/directed treatments and customized prescriptions hold promising open doors for pharmaceutical, bio-pharmaceutical and biotechnology organizations occupied with creating malignancy drugs.

World’s Top Ten Cancer Drugs by 2020

As indicated by the World Health Organization, around 8.2 million individuals bite the dust from disease consistently and it includes an expected 13% of all passing around the world. It is likewise anticipated by the WHO that there will be a 70% expansion in new instances of tumour in the following two decades. Luckily, numerous pharma and biotech organizations are currently concentrating on this need.

A 2016 measurable report from Statista has shown the anticipated best 10 oncology drugs worldwide by 2020. The medications are positioned by income. The rundown is relied upon to be going by Revlimid, a disease tranquilize made by U.S.- based organization Celgene, determined to produce five of the main six malignancy sedates by 2020. Here are the best oncology solutions in detail.

Revlimid (Celgene) Generic Name: Lenalidomide Projected Sales in 2020: $10,110 Million, Imbruvica (AbbVie/J&J) Generic Name: Ibrutinib Projected Sales in 2020: $8,213 Million, Avastin (Roche) Generic Name: Bevacizumab Projected Sales in 2020: $ 6,733 Million, Opdivo (BMS) Generic Name: Nivolumab Projected Sales in 2020: $ 6,201 Million, Xtandi (Medivation & Astellas) Generic Name: Enzalutamide Projected Sales in 2020: $5,700 Million, Rituxan (Roche) Generic Name: Rituximab Projected Sales in 2020: $5,407 Million, Ibrance (Pfizer) Generic Name: Palbociclib Projected Sales in 2020: $4,722 Million, Perjeta (Roche) Generic Name: Pertuzumab Projected Sales in 2020: $4,669 Million, Herceptin (Roche) Generic Name: Trastuzumab Projected Sales in 2020: $4,573 Million, Keytruda (Merck) Generic Name: Pembrolizumab Projected Sales in 2020: $3,560 Million

 

Past Conference Report

World Cancer 2017

The 25th World Cancer Conference was organized on October 19-21, 2017 at Rome, Italy. World Cancer 2017 Congress has received a munificent response from all over the world. This has been conducted with the aim of promoting the developments of new perceptions and ideas for investigating the high level of knowledge reached by scientific community working in the field of Cancer & Oncology.

 The conference was organized around the theme ‘Together towards a cancer free tomorrow. The event imbedded a firm relation of future strategies in the field of Cancer Research with the scientific community.

This conference brought together Leading physicians, surgeons, Clinicians, Professors, Care Specialists, Students and other professionals in which many issues in Oncology field were discussed in depth to provide up-to-date information to the world. On the other hand, the meeting provided an opportunity for networking.

The eminent personalities at the conference were

·         Oliver Micke, Franziskus Hospital Bielefeld, Germany

·         Angiolo Gadducci, University of Pisa, Italy

·         Syed Azizur Rahman, University of Sharjah, UAE

·         Lloyd Jenkins, Budwig Center, Spain

Poster Evaluation Committee and the Winner:

World Cancer 2017 would like to acknowledge Dr. Javier Camacho for his evaluation of the poster session and we are glad to congratulate Ms. Sarah Konard, German Cancer Consortium (DKTK), Germany for receiving the Best Poster Award of the conference.

YRF Evaluation Committee and the Winner:

We would like to acknowledge Dr. Rong Shao for his evaluation of the poster session and we are glad to congratulate Perla Pérez Treviño, Tecnologico de Monterrey (ITESM), Mexico for receiving the Best Poster YRF Award of the conference.

Trailing the success of World Cancer 2017, conference series LLC would like to announce the initiation of the “International Conference on Biomarkers and Cancer Targets” to be held during July 16-17,2018 at Dubai, UAE.


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date December 5-6, 2018

Speaker Opportunity

Supported By

Journal of Cancer Science & Therapy Journal of Integrative Oncology Journal of Carcinogenesis & Mutagenesis

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

mediapartner

Media Partner

mediapartner

Media Partner

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

Collaboration

mediapartner

Media Partner

mediapartner

Media Partner

Collaboration

Collaboration

What People Say....

The International Cancer Epigenetics and Biomarkers Conference 2017 in Osaka was an extremely informative and rewarding opportunity of a lifetime to meet with and hear presentations from the best minds in the field. Personally, I am so very grateful to the Conference Organizing Committee and esteemed colleagues I met for surpassing my expectations in such a truly transformative event.

Speaker

Martyn E Caplin

The conference was very interactive and quite interesting, as I have come from all the way from north Carolina to attend this conference, I have enjoyed every bit of learning new sciences in the field of oncology which is my research field. I am very grateful to the organiser especially omics for inviting me and giving me a chance to present my research work here.

Speaker

HirendraNath Banerjee,Elizabeth City State University, USA

The conference was organized perfectly. I would like to thank organiser for excellent hotel,congress programme, certificate, materials. Thank you for the warm hospitality.

Speaker

Sonya Sergieva, Sofia Cancer Center Sofia, Bulgaria

Thank you for organizing a successful conference! My talk went well and I got to meet and interact with other scientists in closely related aspects of oncology, which was interesting and informative.

Speaker

Joseph O Nwankwo, Federal University, Nigeria

Keytopics

  • Advances In Bone Marrow Transplantation And Surgery
  • Advances In Liquid Biopsy
  • Advances In Malignancy Counteractive Action And Screening
  • Anal Cancer
  • Anti-cancer Drug Delivery
  • Biochemistry Of Cancer
  • Biomarkers And Diagnostics Companies
  • Biomarkers And System Biology
  • Biomarkers In Drug Development
  • Biomarkers: Validation And Verification
  • Bladder Cancer-cystectomy
  • Blastoma
  • Breast Cancer
  • Cancer Alternative Medicine
  • Cancer Bioinformatics
  • Cancer Biopsy
  • Cancer Care Team
  • Cancer Drugs And Cancer Vaccines
  • Cancer Inflamation And Immune Tolerance
  • Cancer Micro Environment
  • Cancer Nanotechnology
  • Cancer Nursing And Care
  • Cancer Pharma Industry
  • Cancer Pharmacology
  • Cancer Prognosis And Predictive Elements
  • Cancer Proteomics
  • Cancer Statistics
  • Cancer Stem Cells
  • Cell Free Biomarkers
  • Clinical Application For Biomarkers
  • Clinical Trials And Case Report
  • Clinicopathology
  • Colorectal Adenoma And Cancer
  • Colorectal Cancer
  • Computational Oncology
  • Computer Assisted Tomography
  • Curative Cancer Treatment
  • Economic Impact On Cancer
  • Endocrine Malignancies
  • Entrepreneurs Investment Meet
  • Etiology Of Cancer
  • Ewing Sarcoma
  • Factors Associated With Cancer Prevalence
  • Gastrointestinal Cancer Immunotherapy
  • Gene Markers
  • Global Market For Cancer Treatments
  • Gynaecologic Oncology
  • Head And Neck Cancers
  • Hepatocellular Carcinoma
  • Hereditary Cancers
  • Juvenile Myelomonocytic Leukemia (JMML)
  • Lumpectomy
  • Metastasis
  • Molecular Epidemiology Of Cancer
  • Nanoparticles In Cancer Therapy
  • Neuro Oncology
  • Non-Hodgkin Lymphoma
  • Novel Approaches To Cancer Therapeutics
  • Oncology And Radiology
  • Oncology Case Reports
  • Organ Based Cancers
  • Oxidative Stress Biomarkers
  • Palliative Cancer Treatment
  • Pathophysiology Of Cancer
  • Pediatric Oncology
  • Predictive Cancer Biomarkers
  • Prognostic Biomarkers
  • Prostaglandins
  • Remission
  • Renal Cell Carcinoma
  • Serum Tumour
  • Squamocellular Carcinoma Blood Disorders
  • Tumor Virology
  • Types Of Biomarker And Biomarkers
  • Types Of Cancers
  • Urinary Biomarkers
  • Urothelial Carcinoma-associated-1
  • Veterinary Hematology